Investorideas.com

Get great ideas from our AI, cannabis, cleantech, crypto, esports and mining podcasts - be a guest or sponsor : 800 665 0411


Share on StockTwits

Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 503 (OTCQX: MRMD) (OTC: EDXC) (OTC: CANQF) (NASDAQ: INM)

 

Delta, Kelowna, BC - December 3, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2020/120320-StocksToWatch.mp3

Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 503 (OTCQX: MRMD) (OTC: EDXC) (OTC: CANQF) (NASDAQ: INM)

SHARE PODCAST:      

Hear Investor ideas cannabis potcast on iTunes

Hear the investor ideas potcast on Spotify

Today's podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today's podcast we will be looking at a few private and public company announcements.

MariMed Inc. (OTCQX: MRMD), a leading multi-state cannabis operator based in Massachusetts, announced the launch of two solventless concentrate products from its wholly owned Nature's Heritage cannabis brand. One-gram jars of kief and bubble hash extracted from a variety of Nature's Heritage strains are now available for purchase at dispensaries across Massachusetts, including the Company's Panacea Wellness dispensary in Middleboro, MA.

"Our kief and bubble hash expand the MariMed product portfolio while meeting the increasingly sophisticated cannabis consumer's demand for flower alternatives and higher potency," said Ryan Crandall, Chief Product Officer and SVP of sales at MariMed. "The response to the quality, flavors, and effects of Nature's Heritage kief has already been very positive in Maryland, and we expect the same in Massachusetts."

Kief is the trichome pollen sifted from dry cannabis flower without the use of chemical solvents. It contains the highest concentration of cannabinoids and terpenes on a cannabis plant, and is often referred to as "cannabis crystals" in reference to its appearance and impressive effects. Similarly, bubble hash is an all-natural solventless cannabis extract created through an ice water extraction process.

"Nature's Heritage kief and bubble hash offer two exceptionally flavorful options for consuming pure and potent cannabis, whether on its own or combined with flower," said Steve Evans, retail manager at Panacea Wellness. "Our customers and patients have spoken, and we're excited to deliver their favorite strains in two new ways."

Nature's Heritage is one of the top-selling cannabis flower brands in Massachusetts and Maryland. With the addition of the kief and bubble hash, the Company continues to grow and expand its portfolio of product offerings under the Nature's Heritage brand. For information and availability, please visit Nature's Heritage at naturesheritagecannabis.com.

Endexx Corporation (OTC: EDXC) (a/k/a "CBD Unlimited"), a lifestyle company focused on the intersection of science, compliance, and formulation of innovative phytonutrient-based food and nutritional products announced an update to shareholders on their global expansion plans.

In a historic vote in Vienna today, "The United Nations Commission on Narcotic Drugs (CND) accepted a World Health Organization (WHO) recommendation to remove cannabis and cannabis resin from Schedule IV of the 1961 Single Convention on Narcotic Drugs."

This World Health Organization recommendation and vote by the UN is the second critical stage to advancing legal changes on cannabis and hemp in all the Industrialized Nations that strictly comply with UN Law. This precedent allows countries like the US, Japan, and Korea to advance new guidelines and laws towards making medicinal cannabis and hemp fully compliant and legal both domestically and globally. As previously mentioned, this ruling opens the potential for banking, insurance, and commodity trading industries to build infrastructure for long-term industry success. Endexx has positioned itself to capitalize directly on this global growth opportunity.

CEO of Endexx, Todd Davis, a known pioneer in the industry, had previously predicted this would occur and recently added, "Domino number two, will change the cannabis industry forever. Cannabis, including Hemp, is no longer illegal and considered a dangerous narcotic and worldwide cannabis and CBD markets will exponentially expand the previously predicted market potential by 1000 fold. This promotes the advancement of Hemp and CBD products to become a worldwide accepted commodity and the potential for Endexx brands such as CBD Unlimited, to become a world leader in the marketplace."

Endexx through its subsidiary, Go Green Global, has recently received two provisional licenses in Jamaica allowing for the sale, cultivation, processing, and distribution of cannabis upon final approval. Jamaica's established history with Ganja, now fully legalized, offers a premium agricultural crop and export to unlock the value of its natural resources and globally positioned ports as the gateway for cannabis to the world markets. The UN vote allows Jamaican officials to expedite exportation compliance standards and open the Jamaican cannabis market to the world.

With these new law changes and the massive new market potential, Endexx via Go Green Global can now position itself to quickly move inventory into the European and worldwide markets with a significant lead over potential competitors.

Endexx has long been a company known for "Science and Compliance", with premium quality, and has received strong critical praise. In addition, CBD Unlimited made significant headway in the industry by showing distribution success establishing real estate in over 6,000 retail stores in the last two years.

Todd Davis added, "This is the big legal "Green Flag" that we have been waiting for and positioned ourselves to take full advantage. Now, with our Jamaican position, we will further target resources towards both Cannabis and CBD distribution worldwide."

The company has recently positioned itself to expand distribution featuring a new high-quality, lower-price point CBD Unlimited product line. This new initiative accelerates expansion efforts with a value product line to attract a wider consumer base to drive strong international growth.

CANAQUEST MEDICAL CORP (OTC: CANQF) a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced that The Journal of Neuroscience has published the findings of Western University's research leading to the discovery of the Mentabinol®, a patented THC based formulation & L-theanine, a compound derived from Green Tea leaves.

The Journal of Neuroscience, a world leading research publication, is a weekly peer-reviewed scientific journal published by the Society for Neuroscience. It covers empirical research on all aspects of neuroscience.

This research showed that when the THC based formulation was combined with the compound L-theanine it protected rats against the negative side-effects that can result from straight THC.

"What we found was that by administering L-theanine along with the THC based formulation, we were able to block several side effects of THC exposure, including changes to schizophrenia-related neurochemical pathways, and abnormalities in behaviors - including cognitive and emotional disturbances," said Dr. Steven Laviolette, a professor at Western's Schulich School of Medicine & Dentistry.

"We started looking at L-theanine because there was strong evidence that it has neuroprotective properties, and previous studies haven't shown any toxicity effects in humans or animals," said Marta De Felice, PhD, a postdoctoral associate in Laviolette's lab and first author on the study.

"It was exciting to see the extent of those changes and we think this is really quite promising. The goal here is to produce a safer formulation for THC that is going to give the benefits without the negative psychiatric side effects. This will be especially beneficial for those who are taking THC for things like long-term pain, chemotherapy side-effects or reducing anxiety or depression." said Laviolette.

Western researchers believe this substance may mitigate this type of harm to chronic cannabis users. The team also concluded that their research provides evidence for combining the THC based formulations with L-theanine to make them safer for both recreational and medicinal use.

Laviolette emphasizes that the University research took place in pre-clinical animal models and he looks forward to moving onto future human clinical trials to study and determine efficacy on humans.

Paul Ramsay, CanaQuest's President/Co-Founder, added, "We believe this important research discovery can help lead to a safer alternative for THC consumers, with our Mentabinol® product providing a viable treatment to help address and alleviate the opioid crisis."

InMed Pharmaceuticals Inc. (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of CBN, today announced that it has secured an exclusive, worldwide license from EyeCRO LLC for its Microemulsion Drug Ocular Penetration System ("MiDROPS®") eyedrop delivery technology targeting effective, topical administration of cannabinoids to the eye.

EyeCRO is a leading contract research organization committed to driving ophthalmic research and development forward to advance new vision-saving treatments. MiDROPS® was developed by EyeCRO as a proprietary platform technology designed to effectively deliver lipophilic molecules to both the anterior and posterior segments of the eye by means of a stable and comfortable eyedrop formulation. InMed has already completed preliminary investigation demonstrating simplicity, superiority and effectiveness of MiDROPS® to deliver sustained levels of CBN to the eye, as compared to other formulations, as part of its INM-088 program for the prospective treatment of ocular diseases, including glaucoma.

The licensing agreement with EyeCRO grants InMed an exclusive, worldwide license to develop and commercialize prospective therapeutic formulations combining MiDROPS® with any and all cannabinoid molecules. EyeCRO will receive consideration in the form of scheduled payments upon the achievement of certain clinical, regulatory and commercial milestones, with such scheduled payments to be made in cash and a nominal amount of securities of InMed which are subject to the approval of the TSX. In addition, EyeCRO stands to receive a low, single digit royalty on any commercial sales of InMed therapeutic products incorporating MiDROPS®. The agreement considers and protects each company's respective intellectual property and patent rights and defines specific provisions for consideration of any new intellectual property that may arise through future development.

With this licensing agreement in place, InMed anticipates initiation of IND-enabling toxicology studies with INM-088, incorporating MiDROPS®, in 2021.

Greentank Technologies Corp. announced today it has received Health Canada approval for a cannabis research license. This marks the first time a cannabis research license has been granted to any vape hardware manufacturer globally, and opens up the opportunity for Greentank to take an industry leadership role in the advancement of vape reliability, performance and safety.

Under the research license, Greentank can handle up to 10,000 grams of dried cannabis flower or 2,500 grams of cannabis extract for research purposes at the company's headquarters in Toronto, Canada. This allows the company to comprehensively test its partners' extracts in house for viscosity, fluidity, constituents, emissions and the various ways those extracts interact with different materials and hardware technologies to determine the best fits for each brand's formulations.

The research license also allows Greentank to import cannabis from legal foreign suppliers and conduct focus-group studies with its brand partners. This data will provide consumer feedback around taste, performance and user experience, as well as critical data surrounding vape emissions and interactions with various materials. Greentank expects its newly expanded research mandate will drastically shorten design cycles and accelerate product development by allowing the company to validate new hardware technologies more efficiently than ever before.

"In an industry that is on the cusp of some major regulatory changes, this research license is a huge milestone achievement for Greentank," says Greentank CEO, Dustin Koffler. "As the only vape hardware manufacturer in the world able to legally conduct formulation testing and research, Greentank is uniquely positioned to lead the way in regulatory compliance adoption. As a trusted advisor to brands we can facilitate first mover advantage in the adoption of new standards surrounding vape safety, reliability and performance by using science and data to validate the entire process."

The announcement coincides with Greentank's construction of its third vape device lab, a state-of-the-art product engineering and development hub operated under the stewardship of Greentank Chief Engineer and former Dyson engineering manager Pete Duckett.

The Greentank device lab represents a new gold standard for the industry, complete with state-of-the-art laboratories and equipment including filling rooms, altitude, thermal shock, and vibration chambers, 3D printers, digital surface and micro-thermal imagers, drop shape analyzers, CNC machining, and even an autoclave.

"It's become clear that one-size-fits-all approaches do not work for THC delivery. This research license provides us with a tremendous opportunity to transform our approach to customization and hardware development to create safer, higher-performing next-generation technologies that will power the future of Greentank and the vape industry, as a whole," says Pete Duckett.

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

Hear Investor ideas cannabis potcast on iTunes

Hear the investor ideas potcast on Spotify

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining the AI Eye.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Follow us on Cannabis Social Media

https://www.facebook.com/Investorideaspotcasts/

https://twitter.com/MJInvestorIdeas

https://www.instagram.com/investorideas_potcast/

Download our Mobile App for iPhone and Android

Contact Investorideas.com

800-665-0411


Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories

Buy a cannabis guest post on Investorideas.com